No registrations found.
ID
Source
Brief title
Health condition
diabetic retinopathy (DR)
Sponsors and support
Intervention
Outcome measures
Primary outcome
treatment success
Secondary outcome
1 year BCVA and macular thickness
Background summary
The aim of this study is to investigate the relationship between advanced glycation end products (AGEs) and treatment
responsiveness to anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) patients.
Study objective
The level of AGEs can predict response to intravitreal anti-VEGF therapy in DME
Study design
baseline, 1 year
Intervention
none
Inclusion criteria
Patients diagnosed with DME who started inravitreal anti-VEGF therapy less than 1 yr ago
· Age: >18 years.
Exclusion criteria
Dark coloured skin (Fitzpatrick type V or VI).
· Skin abnormalities on both arms that will impair the reliability of the autofluorescence
measurement.
· Local or general active infection or inflammatory disease.
· Known renal disease, current dialysis treatment, or a history of renal transplantation.
· Patients with high myopia (>6 diopters), glaucoma, combined retinal disease, media
opacities interfering with OCT imaging, vitreomacular traction on SD-OCT and those
whose SD-OCT images were of poor quality, intraocular surgery within 12 weeks prior
to the first injection
Design
Recruitment
IPD sharing statement
Plan description
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL8431 |
| Other | METc UMCG : METc2019/600 |